Last updated: 2026-02-24 16:52:57 ET
Starting in 2027, the Danish pharma firm will sell its weight-loss and diabetes drugs for $675 per month.
Shares of Blue Owl have sunk 30% this year and appear fairly valued, Deutsche Bank wrote.
Indicators are at extremes — stretched valuations are bearish for stocks.
Why the ‘sell America’ trade may be just that: a cyclical trade, not a structural shift.
The bank upgraded the travel technology company to overweight from equal weight.
Bitcoin ETF investors joined an "institutional exit" this year, but analysis sees a new phase of bullish involvement from bigger players coming next.
Novo Nordisk’s study showing a new drug wasn’t as good as a rival’s led one sell-side analyst to downgrade the stock for the first time in five ...
Booking system freezes and screens crash amid rush of fans trying to secure tickets to 21 March free concertTickets for BTS’s comeback concert in ce...
Cybersecurity stocks are the latest to see sell-off pressure as AI threatens to upend software companies.
AI disruption fears spark sell-off in cyber, but the market is overlooking the sector's fundamentals
